DealExpedition Therapeutics, a San Francisco-based biotech company advancing a next-generation DPP1 inhibitor for COPD, raised $165 million in an oversubscribed Series A fundraising round co-led by Sofinnova Investments and Novo Holdings, with participation from Venrock, BVF Partners, and others.
More on STAT+ →
SERIES A
10/11/2025
Tortugas Neuroscience, a Framingham, MA-based neurology and...
Alesi Surgical, a Cardiff-based surgical smoke management tech, raised £7...
Kelonia Therapeutics, Inc., a Boston-based in‑vivo CAR‑T biotech, was...
brainjo, a Regensburg, Germany-based VR-based mental health platform,...
Açaí Theory, a Bengaluru-based açaí bowl QSR, raised ₹40 million in...
Tava Health, a Salt Lake City-based mental health care platform, raised...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
